Retains Judson Woods for Investor Relations
PROCYON BIOPHARMA INC ("PBP-V") - Retains Judson Woods for Investor Relations
Procyon BioPharma Inc. ("Procyon") announced the engagement of Judson Woods to provide
investor relations services to the Company. Judson Woods assists Canadian companies in
communicating their strategic vision to shareholders and the financial community. The agreement is
subject to review by the relevant regulatory authorities.
Procyon BioPharma Inc. is a publicly traded, biopharmaceutical company focused principally on
advancing two powerful platform technologies that have the potential to diagnose and treat cancer.
Procyon's Antinuclear Autoantibodies (ANAs) bind specifically to multiple cancer cell types strongly
enhancing the immune response to cancer cells. Prostate Secretory Protein (PSP94) is a naturally
occurring human protein that has the potential to treat prostate cancer by inhibiting abnormal
prostate cell growth. In addition, the estimation of PSP94 levels in prostate cancer patients may
have prognostic and diagnostic applications. Procyon also has two late-stage products:
FIBROSTAT(TM), a topical cream for the management of newly formed scars following surgery or
burns and COLOPATH(TM), a rapid, non-invasive screening test for colorectal cancer.
Procyon's shares trade on the CDNX under the ticker symbol, PBP. The Canadian Venture
Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this
release. TEL: (514) 685-9283 Hans J. Mader, President & CEO, Procyon BioPharma Email:
hmader@procyonbiopharma.com Web site: www.procyonbiopharma.com TEL: (514) 843-2309
Nathalie Bourque, Public Relations,
NATIONAL Public Relations TEL: (514) 486-3095 Lorne Woods, Judson Woods, Investor
Relations
______________________________________ |
